# Enanta Pharmaceuticals Inc: financial statements, quarterly

ENTA · Nasdaq · CIK 1177648 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/enta.md) · [Financials](/companies/enta/financials.md) · [Filings](/companies/enta/filings.md) · [Insiders](/companies/enta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/enta/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [18.9 d](/filings/0001193125-25-288121.md) | [18.0](/filings/0000950170-25-018810.md) | [17.1](/filings/0000950170-25-071340.md) | [18.0](/filings/0001193125-25-179795.md) | [14.6 d](/filings/0001193125-25-288121.md) | [17.0](/filings/0001193125-26-046502.md) | [14.9](/filings/0001193125-26-220572.md) | [18.3](/filings/0001193125-26-345719.md) | [15.1 d](/filings/0001193125-25-288121.md) | [18.6](/filings/0001193125-26-046502.md) | [17.2](/filings/0001193125-26-220572.md) | [14.4](/filings/0001193125-26-345719.md) |
| Research and development | $m | [36.2 d](/filings/0001193125-25-288121.md) | [36.4](/filings/0000950170-25-018810.md) | [35.6](/filings/0000950170-25-071340.md) | [28.7](/filings/0001193125-25-179795.md) | [30.8 d](/filings/0001193125-25-288121.md) | [27.7](/filings/0001193125-26-046502.md) | [28.1](/filings/0001193125-26-220572.md) | [27.2](/filings/0001193125-26-345719.md) | [23.8 d](/filings/0001193125-25-288121.md) | [20.9](/filings/0001193125-26-046502.md) | [19.4](/filings/0001193125-26-220572.md) | [22.1](/filings/0001193125-26-345719.md) |
| Operating income | $m | [(31.0) d](/filings/0001193125-25-288121.md) | [(34.9)](/filings/0000950170-25-018810.md) | [(32.8)](/filings/0000950170-25-071340.md) | [(24.2)](/filings/0001193125-25-179795.md) | [(29.9) d](/filings/0001193125-25-288121.md) | [(23.5)](/filings/0001193125-26-046502.md) | [(24.5)](/filings/0001193125-26-220572.md) | [(18.9)](/filings/0001193125-26-345719.md) | [(18.4) d](/filings/0001193125-25-288121.md) | [(11.3)](/filings/0001193125-26-046502.md) | [(11.9)](/filings/0001193125-26-220572.md) | [(17.2)](/filings/0001193125-26-345719.md) |
| Interest expense | $m | [3.2 d](/filings/0000950170-23-065884.md) | [3.4](/filings/0000950170-24-012796.md) | [2.6](/filings/0000950170-24-055581.md) | [2.4](/filings/0000950170-24-092714.md) | [2.6 d](/filings/0001193125-25-288121.md) | [2.0](/filings/0001193125-26-046502.md) | [1.7](/filings/0001193125-26-220572.md) | [1.6](/filings/0001193125-26-345719.md) | [2.4 d](/filings/0001193125-25-288121.md) | [3.1](/filings/0001193125-26-046502.md) | [3.3](/filings/0001193125-26-220572.md) | [4.1](/filings/0001193125-26-345719.md) |
| Income tax | $m | [(1.4) d](/filings/0001193125-25-288121.md) | [(0.6)](/filings/0000950170-25-018810.md) | [(0.4)](/filings/0000950170-25-071340.md) | [(0.4)](/filings/0001193125-25-179795.md) | [(0.4) d](/filings/0001193125-25-288121.md) | [(0.4)](/filings/0001193125-26-046502.md) | [(1.3)](/filings/0001193125-26-220572.md) | [0.0](/filings/0001193125-26-345719.md) | [0.0 d](/filings/0001193125-25-288121.md) | [0.0](/filings/0001193125-26-046502.md) | [0.0](/filings/0001193125-26-220572.md) | [0.0](/filings/0001193125-26-345719.md) |
| Net income | $m | [(28.1) d](/filings/0001193125-25-288121.md) | [(33.4)](/filings/0001193125-25-179795.md) | [(31.2)](/filings/0001193125-25-179795.md) | [(22.7)](/filings/0001193125-25-179795.md) | [(28.8) d](/filings/0001193125-25-288121.md) | [(22.3)](/filings/0001193125-26-345719.md) | [(22.6)](/filings/0001193125-26-345719.md) | [(18.3)](/filings/0001193125-26-345719.md) | [(18.7) d](/filings/0001193125-26-345719.md) | [(11.9)](/filings/0001193125-26-345719.md) | [(13.1)](/filings/0001193125-26-345719.md) | [(19.5)](/filings/0001193125-26-345719.md) |
| Diluted EPS | $ per share | not reported | [(1.58)](/filings/0000950170-25-018810.md) | [(1.47)](/filings/0000950170-25-071340.md) | [(1.07)](/filings/0001193125-25-179795.md) | not reported | [(1.05)](/filings/0001193125-26-046502.md) | [(1.06)](/filings/0001193125-26-220572.md) | [(0.85)](/filings/0001193125-26-345719.md) | not reported | [(0.42)](/filings/0001193125-26-046502.md) | [(0.45)](/filings/0001193125-26-220572.md) | [(0.67)](/filings/0001193125-26-345719.md) |
| Basic EPS | $ per share | not reported | [(1.58)](/filings/0000950170-25-018810.md) | [(1.47)](/filings/0000950170-25-071340.md) | [(1.07)](/filings/0001193125-25-179795.md) | not reported | [(1.05)](/filings/0001193125-26-046502.md) | [(1.06)](/filings/0001193125-26-220572.md) | [(0.85)](/filings/0001193125-26-345719.md) | not reported | [(0.42)](/filings/0001193125-26-046502.md) | [(0.45)](/filings/0001193125-26-220572.md) | [(0.67)](/filings/0001193125-26-345719.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [85.4](/filings/0000950170-24-131260.md) | [39.9](/filings/0000950170-24-012796.md) | [63.5](/filings/0000950170-24-055581.md) | [35.8](/filings/0000950170-24-092714.md) | [37.2](/filings/0001193125-25-288121.md) | [84.3](/filings/0000950170-25-018810.md) | [60.2](/filings/0000950170-25-071340.md) | [44.8](/filings/0001193125-25-179795.md) | [32.3](/filings/0001193125-26-345719.md) | [37.4](/filings/0001193125-26-046502.md) | [34.9](/filings/0001193125-26-220572.md) | [33.4](/filings/0001193125-26-345719.md) |
| Current assets | $m | [423](/filings/0000950170-24-131260.md) | [390](/filings/0000950170-24-012796.md) | [351](/filings/0000950170-24-055581.md) | [287](/filings/0000950170-24-092714.md) | [300](/filings/0001193125-25-288121.md) | [268](/filings/0000950170-25-018810.md) | [243](/filings/0000950170-25-071340.md) | [223](/filings/0001193125-25-179795.md) | [204](/filings/0001193125-26-345719.md) | [199](/filings/0001193125-26-046502.md) | [178](/filings/0001193125-26-220572.md) | [204](/filings/0001193125-26-345719.md) |
| Total assets | $m | [462](/filings/0000950170-24-131260.md) | [428](/filings/0000950170-24-012796.md) | [414](/filings/0000950170-24-055581.md) | [399](/filings/0000950170-24-092714.md) | [377](/filings/0001193125-25-288121.md) | [349](/filings/0000950170-25-018810.md) | [323](/filings/0000950170-25-071340.md) | [301](/filings/0001193125-25-179795.md) | [281](/filings/0001193125-26-345719.md) | [330](/filings/0001193125-26-046502.md) | [315](/filings/0001193125-26-220572.md) | [297](/filings/0001193125-26-345719.md) |
| Current liabilities | $m | [62.8](/filings/0000950170-24-131260.md) | [62.4](/filings/0000950170-24-012796.md) | [54.6](/filings/0000950170-24-055581.md) | [58.2](/filings/0000950170-24-092714.md) | [57.5](/filings/0001193125-25-288121.md) | [49.1](/filings/0000950170-25-018810.md) | [45.9](/filings/0000950170-25-071340.md) | [44.5](/filings/0001193125-25-179795.md) | [48.6](/filings/0001193125-26-345719.md) | [44.7](/filings/0001193125-26-046502.md) | [46.4](/filings/0001193125-26-220572.md) | [54.2](/filings/0001193125-26-345719.md) |
| Total liabilities | $m | [246](/filings/0000950170-24-131260.md) | [237](/filings/0000950170-24-012796.md) | [247](/filings/0000950170-24-055581.md) | [250](/filings/0000950170-24-092714.md) | [248](/filings/0001193125-25-288121.md) | [237](/filings/0000950170-25-018810.md) | [229](/filings/0000950170-25-071340.md) | [222](/filings/0001193125-25-179795.md) | [216](/filings/0001193125-26-345719.md) | [203](/filings/0001193125-26-046502.md) | [198](/filings/0001193125-26-220572.md) | [196](/filings/0001193125-26-345719.md) |
| Shareholders' equity | $m | [217](/filings/0001193125-25-288121.md) | [192](/filings/0001193125-25-179795.md) | [166](/filings/0001193125-25-179795.md) | [149](/filings/0001193125-25-179795.md) | [129](/filings/0001193125-26-345719.md) | [112](/filings/0001193125-26-345719.md) | [93.5](/filings/0001193125-26-345719.md) | [79.3](/filings/0001193125-26-345719.md) | [64.7](/filings/0001193125-26-345719.md) | [127](/filings/0001193125-26-345719.md) | [117](/filings/0001193125-26-345719.md) | [101](/filings/0001193125-26-345719.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(21.6) d](/filings/0001193125-25-288121.md) | [(25.0)](/filings/0000950170-25-018810.md) | [(28.6) d](/filings/0000950170-25-071340.md) | [(14.8) d](/filings/0001193125-25-179795.md) | [(10.4) d](/filings/0001193125-25-288121.md) | [(16.8)](/filings/0001193125-26-046502.md) | [(13.5) d](/filings/0001193125-26-220572.md) | [17.5 d](/filings/0001193125-26-345719.md) | [(6.5) d](/filings/0001193125-25-288121.md) | [(11.7)](/filings/0001193125-26-046502.md) | [(7.2) d](/filings/0001193125-26-220572.md) | [(10.0) d](/filings/0001193125-26-345719.md) |
| Capital expenditure | $m | [1.4 d](/filings/0001193125-25-288121.md) | [0.8](/filings/0000950170-25-018810.md) | [1.7 d](/filings/0000950170-25-071340.md) | [6.5 d](/filings/0001193125-25-179795.md) | [9.0 d](/filings/0001193125-25-288121.md) | [8.7](/filings/0001193125-26-046502.md) | [2.5 d](/filings/0001193125-26-220572.md) | [0.2 d](/filings/0001193125-26-345719.md) | [1.5 d](/filings/0001193125-25-288121.md) | [0.1](/filings/0001193125-26-046502.md) | [0.0 d](/filings/0001193125-26-220572.md) | [0.0 d](/filings/0001193125-26-345719.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.8](/filings/0000950170-24-012796.md) | [21.0](/filings/0000950170-24-055581.md) | [21.1](/filings/0000950170-24-092714.md) | [21.1](/filings/0000950170-25-018810.md) | [21.2](/filings/0000950170-25-071340.md) | [21.2](/filings/0001193125-25-179795.md) | [21.2](/filings/0001193125-26-046502.md) | [21.4](/filings/0001193125-26-220572.md) | [21.4](/filings/0001193125-26-345719.md) | [28.7](/filings/0001193125-26-046502.md) | [29.0](/filings/0001193125-26-220572.md) | [29.1](/filings/0001193125-26-345719.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,125,402 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-345719.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.